8-K - Nektar Therapeutics | StockGist

Current Report Details

Event Type

Regulation Fd

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes

Regulation Fd

8.01

Other Events. Phase 2b RESOLVE-AA Topline Results – 36-Week Induction Treatment Period On December 16, 2025, the Company announced topline results from the 36-w

Other Event

9.01

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued by Nektar Therapeutics on December 16, 2025, furnished herewi

Exhibits Only

Source Document

Exhibits (3)

8-K

99.1

EX-99.1

99.2

EX-99.2